BDNF and Krox20 as Indicators of Platelet-rich Plasma-Induced Nerve Regeneration in a Neuropathic Orofacial Pain Model

Abstract

Objective Various growth factors contained in PRP can increase angiogenesis and cell proliferation, which plays an essential role in the process of neuroregeneration and peripheral nerve injury recovery. This study analyzed PRP effects in the neuro-regeneration of axonotmesis through brain-derived neurotrophic factor (BDNF) and Krox20 expressions.

Materials and Methods Freeze-dried allogeneic platelet-rich plasma (PRP) were prepared from allogeneic sources. Forty-two Rattus norvegicus were divided into three groups: negative control group, positive control group (crushing infraorbital nerve) and treatment group (crushing infraorbital nerve without PRP injection). Each group was observed for fourteen and twenty-one days after injury. Infraorbital nerve tissue is isolated for indirect immunohistochemistry examination with BDNF and Krox20 antibodies. Data analysis was performed using One-Way ANOVA and Mann-Whitney tests with significant value as p < 0.05.

Results The PRP group showed BDNF expression significantly higher than control positive groups, both observation days (p = 0.00). A higher Korx20 expression showed by the PRP group after 21 days than in the control positive groups (p = 0.002).

Conclusion PRP can potentially improve neuroregeneration of axonotmesis through increased BDNF and Krox20 expression on the twenty-one days after injury.

Keywords

peripheral nerve injury - neuro regeneration - BDNF - PRP - Krox20

Authors' Contribution

SW, AS, SW2, NFA, DSE, DR designed the study, performed the data collection, data analysis and interpretation, wrote the manuscript and reviewed the manuscript. All authors declare that they contributed to the critical review of intellectual content and approval of the final version to be published.

Publikationsverlauf

Artikel online veröffentlicht:
13. Juni 2023

• References

• 1 Zimmer Z, Fraser K, Grol-Prokopczyk H, Zajacova A. A global study of pain prevalence across 52 countries: examining the role of country-level contextual factors. Pain 2022; 163 (09) 1740-1750
• 2 Maulina T. The management of orofacial pain in developing countries: the current challenges. Dent Open J 2017; 4 (01) 1-4
• 3 Macfarlane TV, Blinkhorn AS, Davies RM, Kincey J, Worthington HV. Oro-facial pain in the community: prevalence and associated impact. Community Dent Oral Epidemiol 2002; 30 (01) 52-60
• 4 Kumar KH, Elavarasi P. Definition of pain and classification of pain disorders. Journal of Advanced Clinical and Research Insights 2016; 3 (03) 87-90
• 5 Bouhassira D. Neuropathic pain: Definition, assessment and epidemiology. Rev Neurol (Paris) 2019; 175 (1-2): 16-25
• 6 Kandou Manado RD, Amalia AF, Runtuwene T, Kembuan MAHN. Profil nyeri di poliklinik saraf RSUP Prof. Dr. R. D. Kandou Manado periode 1 Januari 2014–31 Desember 2014. Jurnal e-Clinic 2016; 4 (02) 1-7
• 7 Pj W, Derry S, Ra M. et al. Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews. Cochrane Libr 2016; (11) 1-31
• 8 Xie W, Strong JA, Zhang JM. Active nerve regeneration with failed target reinnervation drives persistent neuropathic pain. eNeuro 2017;4(01):ENEURO.0008-17.2017
• 9 Sánchez M, Garate A, Delgado D, Padilla S. Platelet-rich plasma, an adjuvant biological therapy to assist peripheral nerve repair. Neural Regen Res 2017; 12 (01) 47-52
• 10 Jessen KR, Mirsky R. The success and failure of the Schwann cell response to nerve injury. Front Cell Neurosci 2019; 13: 33
• 11 Wong KM, Babetto E, Beirowski B. Axon degeneration: make the Schwann cell great again. Neural Regen Res 2017; 12 (04) 518-524
• 12 Rotshenker S. Wallerian degeneration: the innate-immune response to traumatic nerve injury. J Neuroinflammation 2011; 8 (109) 109
• 13 Conforti L, Gilley J, Coleman MP. Wallerian degeneration: an emerging axon death pathway linking injury and disease. Nat Rev Neurosci 2014; 15 (06) 394-409
• 14 McGregor CE, English AW. The role of BDNF in peripheral nerve regeneration: Activity-dependent treatments and Val66Met. Front Cell Neurosci 2019; 12 (522) 522
• 15 Benarroch EE. Brain-derived neurotrophic factor: Regulation, effects, and potential clinical relevance. Neurology 2015; 84 (16) 1693-1704
• 16 Sasi M, Vignoli B, Canossa M, Blum R. Neurobiology of local and intercellular BDNF signaling. Pflugers Arch 2017; 469 (5-6): 593-610
• 17 Duraikannu A, Krishnan A, Chandrasekhar A, Zochodne DW. Beyond trophic factors: Exploiting the intrinsic regenerative properties of adult neurons. Front Cell Neurosci 2019; 13 (128) 128
• 18 Grosheva M, Nohroudi K, Schwarz A. et al. Comparison of trophic factors' expression between paralyzed and recovering muscles after facial nerve injury. A quantitative analysis in time course. Exp Neurol 2016; 279: 137-148
• 19 Ornitz DM, Itoh N. The fibroblast growth factor signaling pathway. Wiley Interdiscip Rev Dev Biol 2015; 4 (03) 215-266
• 20 Sánchez M, Garate A, Miren Bilbao A. et al. Platelet-Rich Plasma for Injured Peripheral Nerves: Biological Repair Process and Clinical Application Guidelines. Demystifying Polyneuropathy - Recent Advances and New Directions 2019. Available at: http://dx.doi.org/10.5772/intechopen.81104
• 21 Bondy CA, Cheng CM. Signaling by insulin-like growth factor 1 in brain. Eur J Pharmacol 2004; 490 (1-3): 25-31
• 22 Sullivan KA, Kim B, Feldman EL. Insulin-like growth factors in the peripheral nervous system. Endocrinology 2008; 149 (12) 5963-5971
• 23 Sakowski SA, Feldman EL. Insulin-like growth factors in the peripheral nervous system. Endocrinol Metab Clin North Am 2012; 41 (02) 375-393 , vii
• 24 Xu QG, Li XQ, Kotecha SA, Cheng C, Sun HS, Zochodne DW. Insulin as an in vivo growth factor. Exp Neurol 2004; 188 (01) 43-51
• 25 Figlia G. c-Jun in Schwann Cells: Stay Away from Extremes. J Neurosci 2018; 38 (14) 3388-3390
• 26 Knott EP, Assi M, Pearse DD. Cyclic AMP signaling: a molecular determinant of peripheral nerve regeneration. BioMed Res Int 2014; 2014 (651625): 651625
• 27 Taefehshokr S, Key YA, Khakpour M, Dadebighlu P, Oveisi A. Early growth response 2 and Egr3 are unique regulators in immune system. Cent Eur J Immunol 2017; 42 (02) 205-209
• 28 Hung HA, Sun G, Keles S, Svaren J. Dynamic regulation of Schwann cell enhancers after peripheral nerve injury. J Biol Chem 2015; 290 (11) 6937-6950
• 29 Hyung S, Yoon Lee B, Park JC, Kim J, Hur EM, Francis Suh JK. Coculture of primary motor neurons and Schwann cells as a model for in vitro myelination. Sci Rep 2015; 5: 15122
• 30 Wei Z, Fei Y, Su W, Chen G. Emerging role of schwann cells in neuropathic pain: Receptors, glial mediators and myelination. Front Cell Neurosci 2019; 13 (116) 116
• 31 Stettner M, Lohmann B, Wolffram K. et al. Interleukin-17 impedes Schwann cell-mediated myelination. J Neuroinflammation 2014; 11 (63) 63
• 32 Golzadeh A, Mohammadi R. Effect of local administration of platelet-derived growth factor B on functional recovery of peripheral nerve regeneration: A sciatic nerve transection model. Dent Res J (Isfahan) 2016; 13 (03) 225-232
• 33 Qin J, Wang L, Zheng L. et al. Concentrated growth factor promotes Schwann cell migration partly through the integrin β1-mediated activation of the focal adhesion kinase pathway. Int J Mol Med 2016; 37 (05) 1363-1370
• 34 Fletcher JL, Murray SS, Xiao J. Brain-derived neurotrophic factor in central nervous system myelination: A new mechanism to promote myelin plasticity and repair. Int J Mol Sci 2018; 19 (12) 1-16